Selected research
Industry Research
RNA-Targeted Small Molecules Industry Research Report 2026
Market perspective
The global RNA-Targeted Small Molecules market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the RNA-Targeted Small Molecules market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the RNA-Targeted Small Molecules market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the RNA-Targeted Small Molecules market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of RNA-Targeted Small Molecules include Twentyeight-Seven Therapeutics, STORM Therapeutics, Skyhawk Therapeutics, Ribometrix, H3 Biomedicine, Gotham Therapeutics, Expansion Therapeutics, Epics Therapeutics and Arrakis Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global RNA-Targeted Small Molecules market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to RNA-Targeted Small Molecules.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
RNA-Targeted Small Molecules Market by Company
Twentyeight-Seven Therapeutics
STORM Therapeutics
Skyhawk Therapeutics
Ribometrix
H3 Biomedicine
Gotham Therapeutics
Expansion Therapeutics
Epics Therapeutics
Arrakis Pharmaceuticals
Anima Biotech Inc.
Accent Therapeutics
RNA-Targeted Small Molecules Segment by Type
mRNA Translation Regulation
RNA Splicing Modification
Indirect RNA Targeting - Epitranscriptomics
Direct RNA Targeting
RNA-Targeted Small Molecules Segment by Application
Laboratories
Hospitals
Phamacy
RNA-Targeted Small Molecules Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecules and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecules.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of RNA-Targeted Small Molecules companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- mRNA Translation Regulation
- RNA Splicing Modification
- Indirect RNA Targeting - Epitranscriptomics
- Direct RNA Targeting
Applications
- Laboratories
- Hospitals
- Phamacy
Companies covered
- Twentyeight-Seven Therapeutics
- STORM Therapeutics
- Skyhawk Therapeutics
- Ribometrix
- H3 Biomedicine
- Gotham Therapeutics
- Expansion Therapeutics
- Epics Therapeutics
- Arrakis Pharmaceuticals
- Anima Biotech Inc.
- Accent Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 RNA-Targeted Small Molecules by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 mRNA Translation Regulation
- 2.2.3 RNA Splicing Modification
- 2.2.4 Indirect RNA Targeting - Epitranscriptomics
- 2.2.5 Direct RNA Targeting
- 2.3 RNA-Targeted Small Molecules by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Laboratories
- 2.3.3 Hospitals
- 2.3.4 Phamacy
- 2.4 Assumptions and Limitations
3 RNA-Targeted Small Molecules Breakdown Data by Type
- 3.1 Global RNA-Targeted Small Molecules Historic Market Size by Type (2021-2026)
- 3.2 Global RNA-Targeted Small Molecules Forecasted Market Size by Type (2027-2032)
4 RNA-Targeted Small Molecules Breakdown Data by Application
- 4.1 Global RNA-Targeted Small Molecules Historic Market Size by Application (2021-2026)
- 4.2 Global RNA-Targeted Small Molecules Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global RNA-Targeted Small Molecules Market Perspective (2021-2032)
- 5.2 Global RNA-Targeted Small Molecules Growth Trends by Region
- 5.2.1 Global RNA-Targeted Small Molecules Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 RNA-Targeted Small Molecules Historic Market Size by Region (2021-2026)
- 5.2.3 RNA-Targeted Small Molecules Forecasted Market Size by Region (2027-2032)
- 5.3 RNA-Targeted Small Molecules Market Dynamics
- 5.3.1 RNA-Targeted Small Molecules Industry Trends
- 5.3.2 RNA-Targeted Small Molecules Market Drivers
- 5.3.3 RNA-Targeted Small Molecules Market Challenges
- 5.3.4 RNA-Targeted Small Molecules Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top RNA-Targeted Small Molecules Players by Revenue
- 6.1.1 Global Top RNA-Targeted Small Molecules Players by Revenue (2021-2026)
- 6.1.2 Global RNA-Targeted Small Molecules Revenue Market Share by Players (2021-2026)
- 6.2 Global RNA-Targeted Small Molecules Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of RNA-Targeted Small Molecules Head Office and Area Served
- 6.4 Global RNA-Targeted Small Molecules Players, Product Type & Application
- 6.5 Global RNA-Targeted Small Molecules Manufacturers Established Date
- 6.6 Global RNA-Targeted Small Molecules Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America RNA-Targeted Small Molecules Market Size (2021-2032)
- 7.2 North America RNA-Targeted Small Molecules Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 7.4 North America RNA-Targeted Small Molecules Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe RNA-Targeted Small Molecules Market Size (2021-2032)
- 8.2 Europe RNA-Targeted Small Molecules Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 8.4 Europe RNA-Targeted Small Molecules Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific RNA-Targeted Small Molecules Market Size (2021-2032)
- 9.2 Asia-Pacific RNA-Targeted Small Molecules Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 9.4 Asia-Pacific RNA-Targeted Small Molecules Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America RNA-Targeted Small Molecules Market Size (2021-2032)
- 10.2 South America RNA-Targeted Small Molecules Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 10.4 South America RNA-Targeted Small Molecules Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa RNA-Targeted Small Molecules Market Size (2021-2032)
- 11.2 Middle East & Africa RNA-Targeted Small Molecules Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 11.4 Middle East & Africa RNA-Targeted Small Molecules Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Twentyeight-Seven Therapeutics
- 12.1.1 Twentyeight-Seven Therapeutics Company Information
- 12.1.2 Twentyeight-Seven Therapeutics Business Overview
- 12.1.3 Twentyeight-Seven Therapeutics Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.1.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 12.1.5 Twentyeight-Seven Therapeutics Recent Developments
- 12.2 STORM Therapeutics
- 12.2.1 STORM Therapeutics Company Information
- 12.2.2 STORM Therapeutics Business Overview
- 12.2.3 STORM Therapeutics Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.2.4 STORM Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 12.2.5 STORM Therapeutics Recent Developments
- 12.3 Skyhawk Therapeutics
- 12.3.1 Skyhawk Therapeutics Company Information
- 12.3.2 Skyhawk Therapeutics Business Overview
- 12.3.3 Skyhawk Therapeutics Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.3.4 Skyhawk Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 12.3.5 Skyhawk Therapeutics Recent Developments
- 12.4 Ribometrix
- 12.4.1 Ribometrix Company Information
- 12.4.2 Ribometrix Business Overview
- 12.4.3 Ribometrix Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.4.4 Ribometrix RNA-Targeted Small Molecules Product Portfolio
- 12.4.5 Ribometrix Recent Developments
- 12.5 H3 Biomedicine
- 12.5.1 H3 Biomedicine Company Information
- 12.5.2 H3 Biomedicine Business Overview
- 12.5.3 H3 Biomedicine Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.5.4 H3 Biomedicine RNA-Targeted Small Molecules Product Portfolio
- 12.5.5 H3 Biomedicine Recent Developments
- 12.6 Gotham Therapeutics
- 12.6.1 Gotham Therapeutics Company Information
- 12.6.2 Gotham Therapeutics Business Overview
- 12.6.3 Gotham Therapeutics Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.6.4 Gotham Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 12.6.5 Gotham Therapeutics Recent Developments
- 12.7 Expansion Therapeutics
- 12.7.1 Expansion Therapeutics Company Information
- 12.7.2 Expansion Therapeutics Business Overview
- 12.7.3 Expansion Therapeutics Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.7.4 Expansion Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 12.7.5 Expansion Therapeutics Recent Developments
- 12.8 Epics Therapeutics
- 12.8.1 Epics Therapeutics Company Information
- 12.8.2 Epics Therapeutics Business Overview
- 12.8.3 Epics Therapeutics Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.8.4 Epics Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 12.8.5 Epics Therapeutics Recent Developments
- 12.9 Arrakis Pharmaceuticals
- 12.9.1 Arrakis Pharmaceuticals Company Information
- 12.9.2 Arrakis Pharmaceuticals Business Overview
- 12.9.3 Arrakis Pharmaceuticals Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.9.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Product Portfolio
- 12.9.5 Arrakis Pharmaceuticals Recent Developments
- 12.10 Anima Biotech Inc.
- 12.10.1 Anima Biotech Inc. Company Information
- 12.10.2 Anima Biotech Inc. Business Overview
- 12.10.3 Anima Biotech Inc. Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.10.4 Anima Biotech Inc. RNA-Targeted Small Molecules Product Portfolio
- 12.10.5 Anima Biotech Inc. Recent Developments
- 12.11 Accent Therapeutics
- 12.11.1 Accent Therapeutics Company Information
- 12.11.2 Accent Therapeutics Business Overview
- 12.11.3 Accent Therapeutics Revenue in RNA-Targeted Small Molecules Business (2021-2026)
- 12.11.4 Accent Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 12.11.5 Accent Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst